September 14, 2021 @ 12:13 am | Breaking News, Jubak Picks Portfolio, Jubak Top 50 Portfolio |
Sign Up for Jim‘s Newsletter Back on September 4 I posted a video on YouTube and this site “September and October 2021 Worse Than Usual for Investors?” that argued that September, the worst performing month for the Standard & Poor’s 500 from 1950...
February 2, 2021 @ 7:11 pm | Breaking News, Jubak Picks Portfolio, Jubak Top 50 Portfolio, You May Have Missed |
As of 3:15 p.m. today, February 2, in New York, shares of GameStop (GME)were down 56.22% to $98.50. That a big drop from the January 27 closing high o #347.51, but it’s still significantly above th $17.25 price on January 4. Other stocks that have ridden the...
September 14, 2020 @ 7:56 pm | Breaking News |
As of noon New York time today the Standard & Poor’s 500 was up 1.58% and the Dow Jones Industrials had gained 1.37%. The NASDAQ Composite was higher by 2.01% and the Russell 2000 small cap index had picked up 2.11%. The iShares MSCI Emerging Markets ETF...
August 4, 2020 @ 7:34 pm | Breaking News, Jubak Picks Portfolio |
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
June 22, 2020 @ 6:29 pm | Breaking News, INCY, Jubak Picks Portfolio |
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don’t think the gods of investing have repealed the laws of valuation. At...
April 10, 2019 @ 7:57 pm | Breaking News, INCY, Jubak Picks Portfolio, You May Have Missed |
Today on my JubakAM.com subscription site I made Incyte #9 in my 10 Most dangerous Stocks for Earnings Season Special Report–and #5 on my Buy on Any Plunge Bonus Special Report. Here’s what I wrote: “There’s a good chance that Incyte (INCY)...
January 8, 2019 @ 7:50 pm | Breaking News, INCY, IONS, Jubak Picks Portfolio, NKTR, Update, Volatility |
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday’s close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big...
December 3, 2018 @ 7:19 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte’s (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte’s Jakafi in combination...
August 24, 2018 @ 3:56 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
June 1, 2018 @ 7:56 pm | Breaking News, INCY, Volatility |
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
March 15, 2018 @ 6:52 pm | Breaking News, INCY, Jubak Picks Portfolio |
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely...
March 7, 2018 @ 7:03 pm | Breaking News, INCY, Jubak Picks Portfolio |
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out–results from critical drug trials weren’t likely to be reported for two years. The reason to...
December 6, 2017 @ 7:55 pm | Breaking News, INCY, Jubak Picks Portfolio |
On December 4 MacroGenics (MGNX) announced that it had closed on its previously announced (October 25) license agreement with Incyte (INCY). For an upfront payment of $150 million and up to $420 million in milestone payments Incyte gained the exclusive global rights...
November 28, 2017 @ 7:51 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Maybe you didn’t even know there was a biotech dip. If all you’ve been following in the sector is a stock like Nektar Therapeutics (NKTR), a Jubak Picks member (and the call options are a holding in my Volatility Portfolio), you’re likely to respond...
October 2, 2017 @ 7:56 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
This qualifies as a horrendous six months for any stock: Shares of Incyte (INCY) are down from $152.66 on March 15 to $115.19 at the close today, October 2. The shares have been even lower, which is one thing giving me some hope that the pain is coming to an end. The...
May 18, 2017 @ 5:35 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Shares of Incyte (INCY) are up 7.1% as of 12:30 p.m. New York time on data released before the June meeting of the American Society of Clinical Oncology showing that Incyte’s epacadostat, which is an IDO inhibitor, has proved effective when used in combination...
April 18, 2017 @ 7:08 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
I know the headlines on Friday said that the U.S. Food and Drug Administration had “rejected” Olumiant (known more frequently until recently as baricitinib), a new drug for rheumatoid arthritis from Eli Lilly (LLY) and research lead Incyte Corp (INCY.) And...
February 24, 2017 @ 6:25 pm | INCY, Jubak Picks Portfolio, Update |
In a change effective February 28 Incyte (INCY) will replace Spectra Energy (SE) in the Standard & Poor’s 500 stock index. Spectra Energy is being acquired by Enbridge (ENB.) All those index funds and ETFs that track the S&P 500 will have to buy shares...
February 23, 2017 @ 7:34 pm | INCY, Jubak Picks Portfolio, Update |
Usually with a biotech stock you trade the present for the future: no revenue now but the promise of big revenue to come. Incyte’s (INCY) most recent quarter, reported on February 14, doesn’t require that trade off. Which means investors should be asking a...
January 9, 2017 @ 11:24 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Incyte (INCY) ended 2016 with a big deal. The company agreed to pay Merus (MRUS) $120 million and to buy $80 million in Merus stock for the exclusive rights to 11 bispecific antibody programs. The companies will work together to develop and commercialize these...
November 17, 2016 @ 7:33 pm | INCY, Jubak Picks Portfolio, Update |
Incyte (INCY) has been one of the big movers in the biotech rally after Donald Trump’s victory in the November 8 presidential election. The stock is up 26.7% from the close on November 3 to the close today, November 17. (Incyte is a member of my Jubak Picks...